Tuesday Mar 4
Hospira Names David J. Endicott President of Medical Devices
Hospira, Inc. , the world's leading provider of injectable drugs and infusion technologies, today announced that David J. Endicott has been named President, Hospira Medical Devices, effective March 10, 2014.
Trending on the Topix Network
Thu Feb 27, 2014
The Motley Fool
Even With Growth Opportunities Ahead, Is Hospira Overvalued?
A lackadaisical approach to proper plant management has led to numerous FDA warning letters at key plants and a shipment freeze on the company's pumps.
Wed Feb 26, 2014
Company that makes drugs for Ohio executions says it opposes lethal injection
The drug maker that manufactured the two drugs used for Ohio executions says it opposes lethal injection and makes products to save lives, not end them.
Thu Feb 20, 2014
APNewsBreak: Where Ohio got its execution drugs
Ohio's most recent batches of lethal injection drugs were produced by a company that wants states to stop using them for capital punishment, records show.
Fri Feb 14, 2014
Hospira Upgraded to Buy by Jefferson Research
Hospira traded down 0.82% during mid-day trading on Friday, hitting $43.75. 382,025 shares of the company's stock traded hands.
Thu Feb 13, 2014
Hospira confident 'swamp is drained' as Us Fda ups status of Rocky Mount
The US FDA has upgraded Hospira's troubled Rocky Mount, North Carolina plant to VAI status though its 2010 Warning Letter still stands.
Alvogen launches Inflectra in Europe with Hospira
InflectraTM, Europe's first biosimilar monoclonal antibody therapy that has been approved for the treatment of inflammatory conditions including rheumatoid arthritis , ankylosing spondylitis, Crohn's disease , ulcerative colitis , psoriatic arthritis and psoriasis.
Wed Feb 12, 2014
Hospira's CEO Discusses Q4 2013 Results - Earnings Call Transcript
I will now turn the call over to Karen King, Corporate Vice President of Investor Relations.
Hospira Reports Fourth-Quarter and Full-Year 2013 Results
On a U.S. Generally Accepted Accounting Principles basis, fourth-quarter 2013 diluted earnings per share were "In 2013, Hospira made significant progress advancing the company's dual priorities of reinforcing our foundation and turbocharging growth, while also achieving solid financial performance, delivering adjusted* earnings per share at the ... (more)
Tue Feb 11, 2014
Hargreaves Services's "Corporate" Rating Reaffirmed at N+1 Singer
's stock had its "corporate" rating reaffirmed by equities research analysts at N+1 Singer in a research note issued to investors on Tuesday, Analyst Ratings.Net reports.
Mon Feb 10, 2014
Hospira to Present at Upcoming Investor Conferences
The presentations will be available to all interested parties through a live audiocast accessible via the investor relations section of Hospira's website at www.hospirainvestor.com .